KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed EBITDA Margin for 8 consecutive years, with 4.18% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 5065.0% to 4.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.36% through Dec 2025, up 3797.0% year-over-year, with the annual reading at 5.48% for FY2025, 2852.0% up from the prior year.
  • EBITDA Margin hit 4.18% in Q4 2025 for Adaptive Biotechnologies, down from 25.23% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 172.3% in Q4 2023 to a low of 322.32% in Q2 2023.
  • Historically, EBITDA Margin has averaged 74.84% across 5 years, with a median of 74.83% in 2023.
  • Biggest YoY gain for EBITDA Margin was 30604bps in 2024; the steepest drop was -21877bps in 2024.
  • Year by year, EBITDA Margin stood at 162.39% in 2021, then skyrocketed by 56bps to 70.99% in 2022, then soared by 343bps to 172.3% in 2023, then crashed by -127bps to 46.46% in 2024, then surged by 109bps to 4.18% in 2025.
  • Business Quant data shows EBITDA Margin for ADPT at 4.18% in Q4 2025, 25.23% in Q3 2025, and 3.25% in Q2 2025.